PHILADELPHIA, Feb. 4, 2011 /PRNewswire/ -- AVAX Technologies,
Inc. (Pink Sheets: AVXT) ("AVAX" or the "Company") today announced
that it filed a Form 10 with the Securities and Exchange Commission
("SEC"). Upon the effectiveness of this Form 10, AVAX will
once again become a publicly reporting company. The Company
intends to seek to have its common stock trade on the
Over-the-Counter Bulletin Board. The Company's Form 10, which
contains among other things, recent information about the Company's
business, operations, financial results and capitalization, can be
accessed through the website maintained by the SEC at
www.sec.gov.
About AVAX Technologies, Inc.
AVAX Technologies, Inc. is a biotechnology company headquartered
in Philadelphia, PA. The
Company is engaged in the research and clinical and commercial
development of biological products and cancer therapeutics. The
Company's AC Vaccine platform is a therapeutic cancer vaccine.
Forward-Looking Statements
Certain statements in this release are "forward-looking"
statements. Forward-looking statements involve significant
risks and uncertainties, and in light of the significant
uncertainties inherent in such statements, the inclusion of such
information should not be regarded as a representation by the
Company that the objectives and plans of the Company will be
achieved. In fact, actual results could differ materially from
those contemplated by such forward-looking statements. These
statements include, but are not limited to, the Company's immediate
need to obtain additional funding to continue to finance the
Company, the Company's plans, objectives, projections, expectations
and intentions such as those relating to the future development of
M-VAX® and its other vaccine candidates, as well as other important
factors discussed in the Company's Form 10. The Company does
not undertake any obligation to release publicly any revisions to
these forward-looking statements or to reflect the occurrence of
unanticipated events.
SOURCE AVAX Technologies, Inc.
